


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10692303
	Filing Date		2003-10-23
	First Named Inventor		T. Primiano
	Art Unit		1643
	Examiner Name		Lynn Anne Bristol
	Attorney Docket Number		02-1133-C



U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
--------------------	---------	---	----

/Lynn Bristol/

04/24/2007

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692303
Filing Date	2003-10-23
First Named Inventor	T. Primiano
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	02-1133-C

1	Bateman et al., Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders, 1996, EMBO J. 15: 6050-6059	<input type="checkbox"/>
2	Chen et al., Prevention of neuronal cell death by neural adhesion molecules L1 and CHL1, 1999, J. Neurobiol. 2: 428-39	<input type="checkbox"/>
3	Kamiguchi et al., Role of L1 in neural development: what the knockouts tell us, 1998, Mol. Cell. Neurosci. 12: 48-55	<input type="checkbox"/>
4	Thies et al., Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma, 2002, Eur. J. Cancer 3:17 08-1716	<input type="checkbox"/>
5	Miyahara et al., Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1-cell adhesion molecule) on resected small cell lung cancer specimens: in relation to proliferation state, 2001, J. Surg. Oncol. 22: 49-54	<input type="checkbox"/>
6	Kowitz et al., Expression of L1 cell adhesion molecule is associated with lymphoma growth and metastasis, 1993, Clin. Exp. Metastasis 11: 41 9-429	<input type="checkbox"/>
7	Itoh et al., A novel monoclonal antibody against carbohydrates of L1 cell adhesion molecule causes an influx of calcium in cultured cortical neurons, 1992, Brain Res. 15: 233-240	<input type="checkbox"/>
8	Klinz et al., L1 and N-CAM antibodies trigger protein phosphatase activity in growth cone-enriched membranes, 1995, J. Neurochem. 65: 84-95	<input type="checkbox"/>
9	Izumoto et al., Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion, 1996, Cancer Res. 56: 1440-1444	<input type="checkbox"/>
10	Schaefer et al., Activation of the MAPK Signal Cascade by the Neural Cell Adhesion Molecule L1 Requires L1 Internalization, 1999, J. Biol. Chem. 274: 37965-37973	<input type="checkbox"/>
11	Di Sculio et al., L1 antibodies block lymph node fibroblastic reticular matrix remodeling in vivo, 1998, J. Exp. Med., 1953-1963	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10692303
		Filing Date	2003-10-23
		First Named Inventor	T. Primiano
		Art Unit	1643
		Examiner Name	Lynn Anne Bristol
		Attorney Docket Number	02-1133-C

LNB	12	Hoefnagel et al., A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients, 2001, Eur. J. Nucl. Med. 28:359-368,2001	<input type="checkbox"/>
	13	Roninson et al., If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells, 2001, Drug Resistance Updates 4: 303-3 13	<input type="checkbox"/>
	14	Harries and Smith, The development and clinical use of trastuzumab (Herceptin), 2002, Endocr. Relat. Cancer 9: 75-85	<input type="checkbox"/>
	15	Schmid et al., A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis, 2000, J. Neuosci. 2: 4177-4188	<input type="checkbox"/>
	16	Dahrne et al., Disruption of the mouse L1 gene leads to malformations of the nervous system, 1997, Nat. Genet. 17 346-349	<input type="checkbox"/>
	17	Accession No. NM_000425.2.	<input type="checkbox"/>
	18	Oravcová et al., Drug-protein binding sites. New trends in analytical and experimental methodology, 1996, J. Chromat. B 30 677: 1-27	<input type="checkbox"/>
	19	Kuhnz and Gieschen, Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro, 1998, DRUGM ETABOLISAMN D DISPOSITIOVNo, I. 26, pp. 1120-11 27	<input type="checkbox"/>
	20	International Search Report from corresponding PCT application WO2004/037198	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Lynn Bristol/	Date Considered	04/24/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.